Abstract: Mice blah blah blah improvement blah blah decreased inflammation

Confession: I start flagging even at T cell talk these days. When we get to CCR2 antagonists, interleukins 1alpha and 1beta my attention's gone until the conclusions, which have some of the right words.

Arch Ophthalmol. 2009 Jul;127(7):882-7. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2.

Goyal S, Chauhan SK, Zhang Q, Dana R.
Schepens Eye Research Institute, Boston, MA 02114, USA.

OBJECTIVE: To determine the effect of a topical antagonist to the chemokine receptor 2 (CCR2) in a murine model of dry eye disease.

METHODS: The effects of a topical CCR2 antagonist and a vehicle control treatment were studied in murine dry eyes. A controlled environment chamber induced dry eye by exposing mice to high-flow desiccated air. Corneal fluorescein staining and enumeration of corneal CD11b(+) and conjunctival CD3(+) T cells were performed in the different groups. Real-time polymerase chain reaction was performed to quantify expression of different inflammatory cytokine transcripts in the cornea and conjunctiva.

RESULTS: Eyes receiving the formulation containing CCR2 antagonist showed a significant decrease in corneal fluorescein staining and decreased infiltration of corneal CD11b(+) cells and conjunctival T cells compared with the vehicle-treated and untreated dry eye groups. The CCR2 antagonist also significantly decreased messenger RNA expression levels of interleukins 1alpha and 1beta in the cornea, and tumor necrosis factor alpha and interleukin 1beta in the conjunctiva.

CONCLUSION: Topical application of CCR2 antagonist is associated with significant improvement in dry eye disease and is reflected by a decrease in inflammation at the clinical, molecular, and cellular levels. Clinical Relevance Topical application of CCR2 antagonist may hold promise as a therapeutic modality in dry eye disease.